Jennifer Marie Specht MD

Breast Cancer

Jill D. Bennett Endowed Professor Clinical Research Director, Breast Oncology Professor, University of Washington, Division of Medical Oncology Professor, Clinical Research Division, Fred Hutchinson Cancer Center

Join to View Full Profile

1144 Eastlake Ave E.Seattle, WA 98195
Phone+1 206-606-6889

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2002 - 2005
University of WashingtonResidency, Internal Medicine, 1999 - 2002
University of Washington School of MedicineClass of 1999

Certifications & Licensure

FL State Medical License 2022 - Present
WA State Medical License 2002 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer Start of enrollment: 2007 Jun 01
Completed
Phase 2
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer Start of enrollment: 2011 Nov 01
Terminated
Not Applicable
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Start of enrollment: 2016 Mar 16
Terminated
Phase 1
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
No longer available
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Start of enrollment: 2019 Sep 06
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer Start of enrollment: 2018 Dec 06
COMPLETED
PHASE2
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) Start of enrollment: 2020 Jan 15
Recruiting
Phase 1
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
AVAILABLE
Roles: Contact
Niraparib + Dostarlimab in BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, Jennifer M Kachergus, Yaohua Ma
JCO Precision Oncology. 2025-04-01
A compositeF-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026).
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, Jennifer M Kachergus, Yaohua Ma
Breast. 2025-03-01
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.
Natasha B Hunter, Lanell M Peterson, Jennifer M Specht, David A Mankoff, Mark Muzi
Breast Cancer Research. 2025-02-17

Journal Articles

Test-Retest Reproducibility of FDG-PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network
Jennifer M Specht, Jean H Lee, Hannah M Linden, Andrew T Shields, David A Mankoff, Paul E Kinahan, Journal of Nuclear Medicine

Grant Support

Role of ctDNA change as a response measure in the EA1183 patient population and how ctDNA changes correlate with metabolic response by serial FDG PET/CTUNIVERSITY OF WASHINGTON2021–2026
Role of ctDNA change as a response measure in the EA1183 patient population and how ctDNA changes correlate with metabolic response by serial FDG PET/CTNCI2021–2026